Intervention to Increase Screening for Glucocorticoid Induced Diabetes (CDA-GID)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Aim 1: Conduct a single site randomized controlled feasibility trial of a decisional support intervention to reduce ADRLLS by improving providers' adherence to GID prevention measures. Approximately 20 primary care providers (caring for approximately 100 veterans on chronic steroids who have not been screened for diabetes in the last year) will be randomly assigned to receive decisional support for GID prevention measures (automatically-derived orders for hemoglobin A1C, to be co-signed by providers). These providers will be compared with 20 providers (caring for 100 veterans not screened for diabetes in the last year) who are randomly assigned to not receive decisional support for management of GID (i.e. the control group). The trial will be conducted at the VA's Eastern Colorado Health Care System (ECHCS) and will last approximately 6 months. Study administration will be coordinated through the Colorado Research Award Enhancement Program (Colorado REAP).
Aim 1a) Procedural Endpoints: As a feasibility trial, this study includes multiple procedural endpoints, such as provider participation rates, to assess the viability of the intervention, rather than a single primary efficacy outcome measure (for details, pages 6-7).
Aim 1b) Preliminary Estimates of Efficacy: We will determine the Delay Interval-the number of days from when a provider is randomized until the provider orders the GID prevention measure. Use of this continuous measure will maximize the power of this feasibility study, though we will also determine proportions of patients for whom these measures were ordered at six months, so that we may estimate the sample size for a subsequent multi-center randomized control trial.
Aim 1c) Post-trial de-briefing: Using structured interviews, we will examine the opinions of providers after they have participated in the GID feasibility trial, in order to gather additional qualitative data regarding the ADRLL framework and refine the intervention for a subsequent randomized controlled trial. Providers will also complete a brief survey assessing their preference for the intervention.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Liron Caplan
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
- Must be 18-90 years old
- Must be served by the ECHCS VA sytem
- Must have chronic glucocorticoid exposure (greater than or equal to 90 days of oral glucocorticoids)
- Eligible providers will consist of those primary care practitioners within the ECHCS with at least one patient meeting the above criteria. For each veteran, the primary care provider (PCP) will be defined as the patient's current general internal medicine or family practice practitioner. In the rare instance in which the patient has no PCP within the VA system, the specialist with the greatest number of patient encounters during the past 12 months will be eligible for inclusion. For every patient, only one provider will be randomized (to avoid multiple exposure to the intervention for some patients). The consent procedure is described below.
Exclusion Criteria:
- Veterans who have had a hgbA1C test within the previous 12 months will be excluded.
- Providers without eligible patients (described above), will be excluded.
- Providers declining to give consent will be excluded.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Decision Support Intervention
Clinical pharmacists mediated computerized decision support
|
Clinical pharmacists mediated computerized decision support
|
|
Comparador activo: Usual Care
Clinicians' typical approach for GID monitoring
|
clinicians typical apporach for GID monitering
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Delay Interval (Days From Randomization Until the Provider Signs the Order for a hgbA1C Level).
Periodo de tiempo: 6 MONTHS
|
For follow-up laboratory data within the VA system, adherence will be monitored through prospective accrual of administrative data and review of the medical record.
Results will be reported as the proportion receiving the preventive measure versus time, i.e. with Kaplan-Meier plots.
We will then determine the variance of Delay Interval.
For the preliminary measure of efficacy, the Delay Interval will be compared between patients whose providers were assigned to the intervention and patients whose providers did not receive the intervention.
|
6 MONTHS
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Feasibility/Reach/Adoption
Periodo de tiempo: 12 months
|
Measurements of intervention delivery include recruitment numbers and provider Participation Rates for enrollment and retention.
The definition of study feasibility consists of provider enrollment rates >= 50%.
Results reported using descriptive statistics (proportions, means, standard deviations, and ranges).
|
12 months
|
|
Feasibility/Reach/Adoption
Periodo de tiempo: 12 months
|
Measurements of intervention delivery include the "representativeness" of providers (differences between participants/non-participants).
Results reported using descriptive statistics (proportions, means, standard deviations, and ranges).
|
12 months
|
|
Feasibility/Reach/Adoption
Periodo de tiempo: 12 months
|
Measurements of intervention delivery include the rationale used by clinicians declining participation.
Results reported using descriptive statistics (proportions, means, standard deviations, and ranges).
|
12 months
|
|
Feasibility/Reach/Adoption
Periodo de tiempo: 12 months
|
Measurements of intervention delivery include numbers of veterans excluded from the intervention.
Results reported using descriptive statistics (proportions, means, standard deviations, and ranges).
|
12 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Liron Caplan, MD, PhD, Veteran Affairs
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 176843
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .